Research Analysts Offer Predictions for PTGX Q4 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Stock analysts at HC Wainwright cut their Q4 2025 earnings per share estimates for Protagonist Therapeutics in a report released on Monday, November 11th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of $0.87 per share for the quarter, down from their prior estimate of $0.88. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.33 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ FY2028 earnings at $2.81 EPS.

Several other research firms have also recently commented on PTGX. BTIG Research raised their target price on shares of Protagonist Therapeutics from $41.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Wedbush reiterated an “outperform” rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Monday, November 4th. TD Cowen upgraded Protagonist Therapeutics to a “strong-buy” rating in a report on Wednesday, September 25th. JMP Securities lowered their target price on shares of Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating for the company in a report on Wednesday, August 7th. Finally, StockNews.com upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Protagonist Therapeutics presently has a consensus rating of “Buy” and an average target price of $53.57.

Protagonist Therapeutics Stock Down 3.8 %

Shares of Protagonist Therapeutics stock opened at $41.04 on Wednesday. Protagonist Therapeutics has a 52 week low of $15.58 and a 52 week high of $48.89. The firm has a market capitalization of $2.45 billion, a P/E ratio of 15.86 and a beta of 2.17. The firm’s 50 day moving average is $45.66 and its two-hundred day moving average is $38.49.

Institutional Trading of Protagonist Therapeutics

A number of institutional investors have recently modified their holdings of PTGX. Farallon Capital Management LLC boosted its holdings in shares of Protagonist Therapeutics by 1.8% in the 2nd quarter. Farallon Capital Management LLC now owns 5,840,773 shares of the company’s stock valued at $202,383,000 after buying an additional 101,800 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Protagonist Therapeutics by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock valued at $92,373,000 after purchasing an additional 39,055 shares during the period. Pacer Advisors Inc. grew its holdings in Protagonist Therapeutics by 405,061.2% during the third quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company’s stock worth $78,034,000 after purchasing an additional 1,733,662 shares during the period. Perceptive Advisors LLC increased its position in Protagonist Therapeutics by 27.6% during the second quarter. Perceptive Advisors LLC now owns 1,268,735 shares of the company’s stock worth $43,962,000 after buying an additional 274,412 shares during the last quarter. Finally, Millennium Management LLC raised its stake in Protagonist Therapeutics by 2,135.6% in the second quarter. Millennium Management LLC now owns 958,283 shares of the company’s stock valued at $33,205,000 after buying an additional 915,418 shares during the period. 98.63% of the stock is currently owned by institutional investors.

Insider Transactions at Protagonist Therapeutics

In other news, CFO Asif Ali sold 14,203 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a total transaction of $631,891.47. Following the completion of the sale, the chief financial officer now owns 34,960 shares in the company, valued at $1,555,370.40. The trade was a 28.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director William D. Waddill sold 8,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $45.00, for a total value of $360,000.00. Following the completion of the transaction, the director now owns 12,000 shares in the company, valued at $540,000. This represents a 40.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.40% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.